[HTML][HTML] Sunitinib resistance in renal cell carcinoma: From molecular mechanisms to predictive biomarkers
Currently, renal cell carcinoma (RCC) is the most prevalent type of kidney cancer. Targeted
therapy has replaced radiation therapy and chemotherapy as the main treatment option for …
therapy has replaced radiation therapy and chemotherapy as the main treatment option for …
Resistance to systemic therapies in clear cell renal cell carcinoma: mechanisms and management strategies
P Makhov, S Joshi, P Ghatalia, A Kutikov… - Molecular cancer …, 2018 - AACR
Renal cell carcinoma (RCC) is the most common form of kidney cancer. It is categorized into
various subtypes, with clear cell RCC (ccRCC) representing about 85% of all RCC tumors …
various subtypes, with clear cell RCC (ccRCC) representing about 85% of all RCC tumors …
N6-methyladenosine-modified TRAF1 promotes sunitinib resistance by regulating apoptosis and angiogenesis in a METTL14-dependent manner in renal cell …
Y Chen, Z Lu, C Qi, C Yu, Y Li, W Huan, R Wang… - Molecular cancer, 2022 - Springer
Background Sunitinib resistance can be classified into primary and secondary resistance.
While accumulating research has indicated several underlying factors contributing to …
While accumulating research has indicated several underlying factors contributing to …
RRM2 regulates sensitivity to sunitinib and PD‐1 blockade in renal cancer by stabilizing ANXA1 and activating the AKT pathway
Renal cell carcinoma (RCC) is a malignant tumor of the kidneys. Approximately 70% of RCC
cases are clear cell renal cell carcinoma with von Hippel–Lindau (VHL) gene mutation and …
cases are clear cell renal cell carcinoma with von Hippel–Lindau (VHL) gene mutation and …
Exploratory analysis of lenvatinib therapy in patients with unresectable hepatocellular carcinoma who have failed prior PD− 1/PD-L1 checkpoint blockade
T Aoki, M Kudo, K Ueshima, M Morita, H Chishina… - Cancers, 2020 - mdpi.com
Simple Summary Programmed cell death protein 1 (PD− 1)/PD-ligand 1 (PD-L1) blockade is
becoming a novel therapeutic option for a hepatocellular carcinoma. In this work, we …
becoming a novel therapeutic option for a hepatocellular carcinoma. In this work, we …
Tumor grafted–chick chorioallantoic membrane as an alternative model for biological cancer research and conventional/nanomaterial-based theranostics evaluation
AK Mapanao, PP Che, P Sarogni, P Sminia… - Expert Opinion on …, 2021 - Taylor & Francis
Introduction: Advancements in cancer management and treatment are associated with
strong preclinical research data, in which reliable cancer models are demanded. Indeed …
strong preclinical research data, in which reliable cancer models are demanded. Indeed …
Renal cell carcinoma management: a step to nano-chemoprevention
Renal cell carcinoma (RCC) is one of the most common kidney cancers, responsible for
nearly 90% of all renal malignancies. Despite the availability of many treatment strategies …
nearly 90% of all renal malignancies. Despite the availability of many treatment strategies …
Combination of tipifarnib and sunitinib overcomes renal cell carcinoma resistance to tyrosine kinase inhibitors via tumor-derived exosome and T cell modulation
JW Greenberg, H Kim, M Ahn, AA Moustafa, H Zhou… - Cancers, 2022 - mdpi.com
Simple Summary Metastatic renal cell carcinoma continues to have a poor prognosis.
Chemotherapies and immuno-oncologic therapies have garnered increasing importance in …
Chemotherapies and immuno-oncologic therapies have garnered increasing importance in …
Ginsenoside Rh2: A shining and potential natural product in the treatment of human nonmalignant and malignant diseases in the near future
W Guan, W Qi - Phytomedicine, 2023 - Elsevier
Background Ginseng is well-known as one of the most valuable and commonly used
Chinese medicines not only in ancient China but also worldwide including East, Russia …
Chinese medicines not only in ancient China but also worldwide including East, Russia …
Inhibition of cMYC-MAX transcription factors hetero-dimerization with structurally engineered omoMYC to downregulate oncogenic pathways in renal carcinoma
In the current study, we employed, structural informatics, and molecular simulation-based
methods to engineer OmoMyc, a c-Myc dominant negative protein, to design novel mutants …
methods to engineer OmoMyc, a c-Myc dominant negative protein, to design novel mutants …